Explore Metformin dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator data.
Metformin is the most-prescribed type-2-diabetes drug — a small molecule, not a peptide — also sourced in research for longevity and metabolic studies. It ships as tablets or a research-grade powder.
The classical mechanism is inhibition of hepatic gluconeogenesis through partial inhibition of mitochondrial complex I, which raises the AMP:ATP ratio and activates AMP-activated protein kinase (AMPK). AMPK activation reduces hepatic glucose output, improves peripheral insulin sensitivity, and produces a range of downstream metabolic effects (lipid handling, autophagy modulation, mTOR signalling) that underpin the longevity hypothesis. Recent work has emphasized additional mechanisms including effects on the gut microbiome, intestinal AMPK signalling, and direct effects on the lysosomal v-ATPase.[3]
UKPDS 34 (Lancet 1998) established the cardiovascular benefit and mortality reduction of metformin in newly-diagnosed overweight T2D, the foundation of its first-line status.[1] Bannister et al. (Diabetes Obes Metab 2014) reported that T2D patients on metformin had lower all-cause mortality than non-diabetic matched controls.[2] The TAME trial — a proposed 3,000-person, 6-year placebo-controlled trial in non-diabetic older adults — was designed to test whether metformin delays the composite of age-related disease (Barzilai et al.); funding and trial start have been ongoing through 2024–2025.[4] The MILES, MERIT, and other shorter trials have produced mixed data on metformin's effect on exercise-induced mitochondrial adaptations.[5]
FDA-approved for type 2 diabetes (1994) and a range of related metabolic indications. No FDA-approved longevity or anti-aging indication exists; off-label use for that purpose is investigational. Research-grade material elsewhere.
Metformin has a reported half-life of ~6 hours (plasma). The pharmacokinetic reference models an interval of once or twice daily; this is not a measured community cadence or a dosing recommendation. A ~6-hour plasma half-life is why immediate-release metformin is split into two daily doses; it clears largely between doses, with extended-release versions smoothing this out. Pharmacokinetic source: FDA label (Glucophage) human PK. It is catalogued under Other Peptides on WPA.
The WPA community has not yet logged enough Metformin calculator sessions to publish dose, vial size, or bacteriostatic water distributions for it. This page therefore covers what is known about the compound itself; the usage charts fill in as researchers run the calculator.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.